TABLE 1.
Detailed Patient and Sample Data With Observed Mutations of the Lesions Investigated
| Patient No. |
Sex | Age (yrs) |
Lesion Analyzed |
IPMN Nuclear Grade |
Differentiation of Invasive Carcinoma |
Location Within Pancreas |
Maximum Dimension (cm)* |
ERBB2 Mutation |
KRAS Mutation |
BRAF Mutation |
PIK3CA Mutation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 62 | IPMN/border | 2 | N/A | Body | — | A830A | G12D | W551G | |
| 2 | M | 73 | IPMC/inv | 3 | Moderate | Head/body | 4 | G12D | |||
| 3 | M | 67 | IPMC/inv | 3 | Moderate | Head | — | G12V | |||
| 4 | M | 69 | IPMC | 3 | N/A | Head | 3.5 | G12V | S1015F | ||
| 5 | F | 75 | IPMC/inv | 3 | Moderate | Head | 5.5 | T324I | |||
| 6 | F | 68 | IPMC/inv | 3 | Moderate | Head | 5 | G12V | |||
| 7 | M | 65 | IPMN/border | 2 | Poor† | Head | 5 | ||||
| 8 | F | 66 | IPMN/border | 2 | N/A | Unc.proc. | 2 | G12V | |||
| 9 | M | 84 | IPMC/inv. | 3 | Moderate | Head | 5 | ||||
| 10 | M | 53 | IPMN/aden | 1 | N/A | Head | 3.5 | G12V | |||
| 11 | M | 71 | IPMC/inv | 2–3 | N/A | Head | — | ||||
| 12 | M | 81 | IPMC | 3 | N/A | Head | 2.5 | ||||
| 13 | M | 63 | IPMC | 3 | Moderate/poor† | Head | 2.3 | ||||
| 14 | M | 66 | IPMC/inv | 3 | Moderate/poor | Head | 6 | H1047R | |||
| 15 | F | 70 | IPMC/inv | 3 | Moderate/poor | Head/body | 7 | G12R | S615F | ||
| 16 | F | 70 | IPMC/inv | 3 | Moderate | Head | 1.5 | ||||
| 17 | M | 72 | IPMN/border | 2 | N/A | Head | 0.4 | ||||
| 18 | F | 53 | mucin.cystad | 1 | N/A | Head | 3 | ||||
| 19 | M | 79 | IPMC/inv | 3 | Moderate/poor | Head | 6 | G12R | |||
| 20 | M | 63 | IPMC/inv | 3 | Moderate/poor | Head | 3.5 | G12R | |||
| 21 | M | 77 | IPMN/aden | 1 | N/A | Head/body | 2.2 | ||||
| 22 | F | 62 | Mucin.cystad | 1 | N/A | Head | 2 | ||||
| 23 | M | 41 | IPMC/inv | 3 | Moderate/poor | Head | 5 | ||||
| 24 | M | 71 | IPMC/inv | 3 | Moderate/poor | Head | 1.5 | ||||
| 25 | F | 58 | IPMN/aden | 1 | N/A | Head | 1.5 | ||||
| 26 | M | 49 | IPMC/inv | 3 | Moderate | Head | 4.5 | ||||
| 27 | M | 71 | IPMC/inv | 3 | Moderate/poor | Head | 5.5 | G12D | |||
| 28 | M | 74 | IPMC | 3 | Well† | Head/body | — | ||||
| 29 | M | 59 | IPMC | 3 | Poor† | Head | 7 | G12V | |||
| 30 | M | 81 | IPMC/inv | 3 | Moderate/poor | Head | 3 | ||||
| 31 | F | 80 | IPMC/inv | 3 | Moderate/poor | Head | 5 | G12R | |||
| 32 | F | 66 | IPMC/inv | 3 | Poor | Head | 3 | ||||
| 33 | F | 77 | IPMC/inv | 3 | Poor | Head | 3 | ||||
| 34 | M | 73 | IPMC/inv | 3 | Poor | Head | 5.5 | G12D | |||
| 35 | F | 77 | IPMC/inv | 3 | Well | Head | 3.2 | G12D | |||
| 36 | F | 61 | IPMC/inv | 3 | Well | Head | 1 | G12D | |||
| 37 | M | 62 | IPMC/inv | 3 | Moderate | Head | 2.2 | ||||
| 38 | F | 59 | IPMC/inv | 3 | Moderate | Head | 3.4 | G12D |
*
Maximum tumor size includes both invasive and noninvasive components of tumor.
†
Invasive carcinoma was associated with IPMN/IPMC in pancreatic resection, but lesion analyzed did not sample invasive carcinoma.
F indicates female; IPMN/aden, IPMN adenoma; IPMN/border, IPMN borderline; IPMC/inv, IPMC with invasion; M, male; mucin.cystad, mucinous cystadenomas; N/A, not applicable; —, not available; Unc.proc, uncinate process.